FDA warned Eugia Pharma Specialities that flawed aseptic line design and poor aseptic practices at its Kolthur Village plant risk contaminating sterile injectables.
What happened
FDA inspected Eugia's sterile injectable drug manufacturing site at Kolthur Village, India, from February 16 to 27, 2026. Inspectors found that the aseptic filling lines were not fully closed barrier systems, that operators frequently reached into the critical high-cleanliness (ISO 5) zone, and that staff used poor aseptic technique such as touching sterile parts and leaning over open transfer hoses. FDA also noted similar violations at two other Eugia sites in the company's network, both now rated Official Action Indicated (FDA's lowest compliance status).
What FDA found
The sterile filling lines were not fully enclosed barrier systems, so operators regularly entered the critical ISO 5 area and disrupted sterile airflow over open vials.
21 CFR 211.42(c)(10)Extended ISO 5 areas where critical aseptic connections were made were not held to ISO 5 limits, and FDA said the company's review of past environmental monitoring was inadequate.
21 CFR 211.42(c)(10)Operators touched sterile parts of the barrier system during setup, brushed gown sleeves against open containers, and did not re-disinfect afterwards.
21 CFR 211.113(b)During production, operators reached their heads and shoulders over an open transfer hose and left barrier doors open, exposing the line to lower-quality air.
21 CFR 211.113(b)Process simulations (media fills, where growth media replaces product to show the line can stay sterile) did not include all critical interventions, such as an aseptic connection, even though many batches were made after the requalification.
21 CFR 211.113(b)Similar aseptic practice and line design failures were cited at Eugia Units II and III, showing management oversight across the network is inadequate.
What FDA wants
FDA wants an independent contamination-hazard risk assessment, a detailed remediation plan with timelines for redesigning and requalifying the aseptic lines and cleanrooms, an assessment of aseptic practices and media fill programme, and a written response within 15 business days. FDA also asks the company to contact its Drug Shortages Staff if compliance actions could disrupt supply.
Who should pay attention
- pharmacies, hospitals and distributors supplied with sterile injectables from this site
- companies that contract this manufacturer to make sterile products for them
- regulatory and quality teams at other sites owned by the same parent company
This is a summary. Read the original letter on fda.gov.